#1 Clinical Trials Search in Europe

Efficacy and Safety of Transmucosal Midazolam for Proportional Palliative Sedation in Children with Refractory Symptoms

2 1 1 1

What is this study about?

Children who have refractory symptoms—symptoms that cannot be controlled with standard medicines—are the focus of this study. The medication being examined is midazolam, which is given by placing it on the lining of the mouth (transmucosal use). The dose is calculated based on the child’s weight and is adjusted to provide the amount of calm needed, a method called proportional sedation.

The purpose of the study is to describe how well proportional sedation with transmucosal midazolam works and how well it is tolerated in pediatric palliative patients who have refractory symptoms.

Participants will receive the medication as prescribed, with regular observations to see how the symptoms respond and to monitor safety. The study follows each child for a period of time, collecting information on symptom relief and any side effects, before concluding the observation phase.

1 enrollment and consent

after joining the study you will be asked to read and sign a consent form that explains the purpose of the research and what is expected from you.

your legal guardian will also need to provide consent because the study involves children.

2 baseline assessment

the study team will collect information about your current health, weight, and the symptoms that are not responding to usual treatment.

this information helps determine the appropriate amount of medication and provides a reference point for later comparisons.

3 medication preparation and dose calculation

you will receive the study medication, which is midazolam formulated for oromucosal (inside the mouth) use.

the dose is calculated as 0.15 mg/kg (milligrams per kilogram of body weight). for example, a child weighing 20 kg would receive 3 mg of the medication.

the exact amount will be prepared by the study staff based on your recorded weight.

4 administration of the medication

the medication is placed on the mucous membrane in the mouth and allowed to dissolve.

you or your caregiver will be instructed on how to position the dose so it can be absorbed through the mouth lining.

5 observation and monitoring

after taking the medication, you will be observed for signs of sedation and any side effects.

the study staff will record how well the sedation works and note any reactions such as changes in breathing, heart rate, or comfort level.

this monitoring continues for the period defined by the study protocol, which is tailored to each participant’s needs.

6 follow‑up assessments

periodic check‑ins will be scheduled to evaluate the ongoing effectiveness of the sedation and to adjust the dose if necessary.

during each visit, the same information about symptoms and side effects will be collected.

7 completion of participation

your involvement in the study will end when the study team determines that the research objectives have been met for you, or if you choose to stop participation.

after completion, you will receive a summary of the observations made during your time in the trial.

Who Can Join the Study?

  • Must be younger than 18 years old when the consent form is signed.
  • If the patient is a girl who could become pregnant, she must agree to use a highly effective birth control method such as pills, patches, injections, implants, an intra‑uterine device, tubal ligation, a partner’s vasectomy, or sexual abstinence.
  • Must be receiving palliative care (care that focuses on comfort) from a pediatric palliative care team.
  • Must have a refractory symptom—a symptom that does not get better with usual treatments—of any type.
  • Must need treatment with midazolam (a medication used for symptom control) for that refractory symptom.
  • Must not have a usable central venous line (a tube placed in a large vein) or must refuse to use it.
  • Parents must be able to follow the study steps and collect the required data for the entire study period.
  • Must be covered by the national health insurance system.
  • Parents must sign the informed consent form for participation.
  • Parents must accept that their child could die at home.

Who Cannot Join the Study?

  • You have taken midazolam (a medication used for calming) within the last 24 hours; the study requires that you have not used this drug in the past day.
  • You have already taken part in the earlier SETRAPED study; participants cannot join this study more than once.
  • You are a female who is currently pregnant or breastfeeding; the study does not include pregnant or nursing mothers.
  • You have a known problem that makes oromucosal midazolam unsafe, such as an allergy to benzodiazepines (the drug family that includes midazolam) or any ingredient in the medicine, a condition called myasthenia gravis (a disease that causes muscle weakness), severe long‑term breathing problems (chronic respiratory insufficiency), a sleep disorder called sleep apnea syndrome (brief pauses in breathing while asleep), or serious liver disease (severe hepatic impairment).
  • Your parents cannot read or understand French; the study requires parents who can read and understand French.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Oncopole Claudius Regaud Toulouse France
University Hospital Of Clermont-Ferrand Clermont Ferrand France
Centre Hospitalier Universitaire De Bordeaux Bordeaux France
Aix Marseille University Marseille France

Other Sites

Site Name City Country Status
Centre Hospitalier Universitaire De Poitiers Poitiers France
CHRU de Besançon Besançon France
Clsgjg Hglastpbnom Rfgcfxkg Uyiozbtfgezqp Dh Txofa Tours France
Cwanmq Lqaw Bozlxb Lyon France
Cgj Ampaqw &txwatj Gsvmqm Hqdvpujfpyr Szk Amiens France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not yet recruiting
17.04.2026

Trial locations

Investigated Drugs:

Midazolam is a medication that helps calm patients by slowing down brain activity. In this study, it is given through the mouth’s lining (such as under the tongue) so it works quickly without needing an injection. The drug is being tested to see how well it can provide gentle, adjustable sedation for children who are in palliative care and have symptoms that cannot be controlled by other treatments. Researchers are looking at how effective it is at keeping the child comfortable and how well it is tolerated, meaning they are watching for any side effects or problems while it is used.

Trial ID:
2025-523840-11-00
Protocol code:
ET25-085
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of testosterone supplementation to improve quality of life in male patients receiving palliative care who have androgen deficiency

    Recruiting

    2 1 1 1
    Belgium

  • Study of psilocybin therapy for psychological distress in patients with COPD, ALS, multiple sclerosis, or atypical Parkinson’s disorders

    Recruiting

    2 1 1
    Investigated Drugs:
    Czechia Denmark The Netherlands Portugal